CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma

Clinical and Translational Gastroenterology

Volumn 3, Issue , 2012, Pages

  Liao, Wei Chih ^a,b   Wang, Hsiu Po ^a   Huang, Hsin Yi ^a   Wu, Ming Shiang ^a   Chiang, Hung ^c   Tien, Yu Wen ^a   Lin, Yu Lin ^a,d   Lin, Jaw Town ^a,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Taipei Institute of Pathology   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PANCREATOSPLENECTOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL;

EID: 84866056928     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2012.18     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Sperti C, Pasquali C, Piccoli A et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21: 195-200. (Pubitemid 27053441)
3. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
4. Sener SF, Fremgen A, Menck HR et al. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
5. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277. (Pubitemid 46143304)
6. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008; 299: 1019-1026. (Pubitemid 351347058)
7. Twombly R. Adjuvant chemoradiation for pancreatic cancer: Few good data, much debate. J Natl Cancer Inst 2008; 100: 1670-1671.
8. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445. (Pubitemid 28135672)
9. Struyf S, Proost P, Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 2003; 81: 1-44. (Pubitemid 38009040)
10. Andre F, Cabioglu N, Assi H et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006; 17: 945-951. (Pubitemid 43778984)
11. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
12. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004; 14: 181-185. (Pubitemid 38586743)
13. Saur D, Seidler B, Schneider G et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 2005; 129: 1237-1250. (Pubitemid 41446863)
14. Kim J, Mori T, Chen SL et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006; 244: 113-120. (Pubitemid 44297455)
15. Kim J, Takeuchi H, Lam ST et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23: 2744-2753. (Pubitemid 46179464)
16. Phillips RJ, Burdick MD, Lutz M et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167: 1676-1686. (Pubitemid 36760683)
17. Marchesi F, Monti P, Leone BE et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64: 8420-8427. (Pubitemid 39491782)
18. Mori T, Doi R, Koizumi M et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004; 3: 29-37. (Pubitemid 39193676)
19. Micallef IN, Stiff PJ, DiPersio JF et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: Results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.
20. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323. (Pubitemid 47355323)
21. Marechal R, Demetter P, Nagy N et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009; 100: 1444-1451.
22. Gebauer F, Tachezy M, Effenberger K et al. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol 2011; 104: 140-145.
23. Maeda S, Shinchi H, Kurahara H et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-1397. (Pubitemid 351543575)
24. Edge SB, Byrd DR, Compton CC et al. Exocrine pancreas. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual, 7th edn. Springer- Verlag: New York, 2009, pp. 241-249.
25. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: Klein JP, Moeschberger ML (eds). Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn. Springer-Verlag: New York, 2003, pp. 276-282.
26. Allison PD. Estimating parametric models with PROC LIFEREG. In: Allison P (ed). Survival Anlysis Using the SAS System: A Pratical Guide. SAS Institute Inc.: Cary, 1995 pp. 61-109.
27. Klein JP, Moeschberger ML. Inference for parametric regression models. In: Klein JP, Moeschberger ML (eds). Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn. Springer-Verlag: New York, 2003, pp. 393-409.
28. Kleinbaum DG, Klein M. Parametric survival models, In: Kleinbaum DG, Klein M (eds). Survival Analysis: A Self-Learning Text, 2nd edn. Springer-Verlag: New York, 2005, pp. 258-330.
29. Sayehmiri K, Eshraghian MR, Mohammad K et al. Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models. J Exp Clin Cancer Res 2008; 27: 74.
30. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
31. von Elm E, Altman DG, Egger M et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 2007; 335: 806-808. (Pubitemid 350057266)
32. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 2003; 237: 74-85. (Pubitemid 36622320)
33. Thomas RM, Kim J, Revelo-Penafiel MP et al. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 2008; 57: 1555-1560.
34. Wehler T, Wolfert F, Schimanski CC et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep 2006; 16: 1159-1164.
35. Koshiba T, Hosotani R, Miyamoto Y et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 2000; 6: 3530-3535.
36. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2: 581-587. (Pubitemid 37361749)
37. Sabattini E, Bisgaard K, Ascani S et al. The EnVision++ system: A new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998; 51: 506-511. (Pubitemid 28375029)
38. Packeisen J, Korsching E, Herbst H et al. Demystified.tissue microarray technology. Mol Pathol 2003; 56: 198-204.
39. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210. (Pubitemid 38339364)
40. Hess KR, Varadhachary GR, Taylor SH et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106: 1624-1633.
41. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
42. Fidler IJ, Yano S, Zhang RD et al. The seed and soil hypothesis: Vascularisation and brain metastases. Lancet Oncol 2002; 3: 53-57. (Pubitemid 34121146)
43. Li D, Xie K, Wolff R et al. Pancreatic cancer. Lancet 2004; 363: 1049-1057. (Pubitemid 38410779)
44. Huguet F, Girard N, Guerche CS et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277.
45. Simons JP, Shah SA, Ng SC et al. National complication rates after pancreatectomy: Beyond mere mortality. J Gastrointest Surg 2009; 13: 1798-1805.
46. Rothman KJ, Greenland S, Lash TL. Validity in epidemiologic studies. In: Rothman KJ, Greenland S, Lash TL (eds). Modern Epidemiology, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, 2008, pp. 128-147.
47. Neoptolemos JP, Stocken DD, Tudur Smith C et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009; 100: 246-250.